TuHURA Biosciences, Inc./NV
HURADrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How HURA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IFx-Hu2.0 | Phase 3 | Advanced Or Metastatic Merkel Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TuHURA Biosciences, Inc./NV's drug pipeline?→
CatalystAlert tracks 1 drug candidate in TuHURA Biosciences, Inc./NV's (HURA) pipeline across Phase 3. Its lead program is IFx-Hu2.0 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TuHURA Biosciences, Inc./NV's next FDA catalyst?→
TuHURA Biosciences, Inc./NV's (HURA) next tracked catalyst is a Phase 3 expected March 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HURA biotech catalysts?→
Add HURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TuHURA Biosciences, Inc./NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.